This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
Data are available from the authors upon reasonable request and with permission of the EBMT.
References
Leonard A, Bertaina A, Bonfim C, Cohen S, Prockop S, Purtill D, et al. Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2021. https://doi.org/10.1016/j.jcyt.2021.09.003.
Iqbal M, Reljic T, Corbacioglu S, de la Fuente J, Gluckman E, Kumar A, et al. Systematic review/meta-analysis on efficacy of allogeneic hematopoietic cell transplantation in sickle cell disease: an international effort on behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. Transpl Cell Ther. 2021;27:167.e1–12. https://doi.org/10.1016/j.jtct.2020.10.007.
Oikonomopoulou C, Goussetis E. HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe. Bone Marrow Transplant. 2021;56:2882–8. https://doi.org/10.1038/s41409-021-01461-0.
Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease: updates and future directions. Hematol Am Soc Hematol Educ Program. 2021;2021:181–9. https://doi.org/10.1182/hematology.2021000251.
Veloski J, Tai S, Evans AS, Nash DB. Clinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual. 2005;20:151–7. https://doi.org/10.1177/1062860605274520.
Mekelenkamp H, van Zanten H, de Vries M, Lankester A, Smiers F. How to facilitate decision-making for hematopoietic stem cell transplantation in patients with hemoglobinopathies. The perspectives of healthcare professionals. Front Pediatr. 2021;9:690309. https://doi.org/10.3389/fped.2021.690309.
Acknowledgements
We thank all respondents who participated in the survey.
Author information
Authors and Affiliations
Contributions
Conception and design of the work: HM, MV, AL, FS, AHP, and MHA. Data collection: HM, TS, and KK. Data analysis and interpretation: BM, HM, TS, JB, and FS. Drafting the article: HM, BM, MV, AL, and FS. Revision of the article: HM, BM, MV, AL, FS, AHP, TS, JB, KK, MHA, BN, and SC.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Mekelenkamp, H., de Vries, M., Markovitch, B. et al. Decision making on HSCT in patients with hemoglobinopathies; an EBMT Pediatric Diseases Working Party and Inborn Errors Working Party scenario-based survey on physicians’ perspectives. Bone Marrow Transplant 58, 584–586 (2023). https://doi.org/10.1038/s41409-023-01926-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-023-01926-4